Rhumbline Advisers Buys 5,428 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Rhumbline Advisers boosted its holdings in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 3.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 151,787 shares of the biotechnology company's stock after acquiring an additional 5,428 shares during the period. Rhumbline Advisers owned 0.19% of Axon Enterprise worth $79,832,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Fourth Dimension Wealth LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter worth approximately $30,000. Y.D. More Investments Ltd bought a new stake in shares of Axon Enterprise in the fourth quarter worth $45,000. Elequin Capital LP acquired a new stake in Axon Enterprise during the fourth quarter valued at approximately $46,000. Stonebridge Financial Group LLC bought a new stake in Axon Enterprise during the fourth quarter valued at $53,000. Finally, GPS Wealth Strategies Group LLC increased its stake in Axon Enterprise by 74.1% during the fourth quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 40 shares during the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Stock Up 0.7%

Shares of AXON traded up $5.22 on Friday, hitting $793.58. The company's stock had a trading volume of 131,265 shares, compared to its average volume of 728,502. Axon Enterprise, Inc. has a fifty-two week low of $278.24 and a fifty-two week high of $798.16. The firm's fifty day moving average price is $638.88 and its 200-day moving average price is $615.19. The firm has a market capitalization of $61.78 billion, a price-to-earnings ratio of 205.06, a P/E/G ratio of 5.17 and a beta of 1.24. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating the consensus estimate of $1.34 by $0.07. The company had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The firm's revenue for the quarter was up 31.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.15 EPS. On average, equities research analysts expect that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Wall Street Analyst Weigh In

AXON has been the subject of a number of recent analyst reports. Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. Barclays upped their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. Northcoast Research downgraded Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. The Goldman Sachs Group upped their target price on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. Finally, Bank of America upped their target price on Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a report on Wednesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $699.55.

Insider Activity

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the firm's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the sale, the chief executive officer now owns 3,063,982 shares of the company's stock, valued at $1,657,583,622.18. This trade represents a 0.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeri Williams sold 307 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $552.72, for a total value of $169,685.04. Following the sale, the director now directly owns 1,627 shares of the company's stock, valued at $899,275.44. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 43,969 shares of company stock valued at $29,909,594. 4.40% of the stock is owned by insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.